Ultragenyx Pharmaceutical shares are trading higher after the company announced the FDA approval of FAYUVI for treatment of pediatric patients with mucopolysaccharidosis type IIIA.

Benzinga News-desk www.benzinga.com Positive 94.9%

Neg 0% Neu 0% Pos 94.9%

Comments

No comments yet. Be the first!